Drug Profile

Research programme: small activating RNA therapeutics - AstraZeneca/MiNA therapeutics

Latest Information Update: 28 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca; MiNA Therapeutics; University of California at San Francisco
Developer AstraZeneca; MiNA Therapeutics
Class RNA
Mechanism of Action RNA stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2024 No recent reports of development identified for research development in Metabolic-disorders in United Kingdom (Parenteral)
17 Jan 2020 MiNA Therapeutics has patent protection for saRNA technology platform in USA granted before January 2020 (MiNA Therapeutics website, January 2020)
09 Jan 2020 Early research in Metabolic disorders in United Kingdom (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com